Pharming Group N.V.
Submit Your Information
If you suffered a loss on your Pharming Group N.V. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.
Background
On July 30, 2026, the Company reported second quarter earnings, including revenue of $90.2 million, reflecting a 3.2% year over year decline. Further, the Company reported a 10% revenue decline for RUCONEST. The Company stated, among other things, that “the year-over-year decline reflected... temporary inventory normalization." The Company also cut its full year revenue guidance approximately $30 million at the midpoint to $375 to $395 million and stated “[a]t the midpoint of our guidance range, RUCONEST U.S. revenue is expected to decline approximately 3% for the full year."
On this news, Pharming Group shares fell $1.26 or 10.5% per share to close at $10.75, on July 30, 2026, thereby injuring investors.
Submit Your Information